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Abstract
Preclinical data suggest that medroxyprogesterone acetate (MPA) has both anti-metastatic and 
anti-angiogenic activity in the absence of hormone receptors (HR). This phase II trial assessed the 
activity of MPA alone or in combination with low-dose chemotherapy in patients with metastatic 
HR-negative breast cancer. Postmenopausal women with HR-negative disease were eligible if they 
had not received more than 3 chemotherapy regimens for metastatic disease. All patients were 
treated with MPA 1,000–1,500 mg/day orally; patients in cohort two also received low-dose oral 
cyclophosphamide and methotrexate (ldCM, 50 mg/day and 2.5 mg twice daily on Days 1 and 2 
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each week). Tissue and circulating biomarkers were assessed serially. The primary endpoint was 
clinical benefit response defined as objective response or stable disease ≥6 months. Thirty patients 
were enrolled (14 MPA monotherapy; 16 MPA + ldCM); median age was 55 (35–80); nearly all 
had visceral involvement. Despite dose escalation in 90 % of patients, only 17 (57 %) patients ever 
achieved MPA trough concentrations >50 ng/ml. One patient developed grade 4 renal failure in 
the setting of rapid disease progression and dehydration. There were no objective responses. One 
patient in each cohort (~7 %) had stable disease for > 6 months. Skin Nm23 expression increased 
after 4 weeks of MPA + ldCM, but there were no significant changes in TSP-1, PAI-1 antigen, or 
PAI-1 activity. MPA had limited activity and does not warrant further development in patients with 
HR-negative advanced breast cancer. Poor bioavailability limited exposure despite dose escalation.
Keywords
Glucocorticoid receptor; Metastasis suppressor gene; Angiogenesis; Thrombospondin-1; Nm023; 
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Critical features of malignancy include uncontrolled proliferation, insensitivity to negative 
growth regulation, evasion of apoptosis, lack of senescence, invasion and metastasis, 
angiogenesis, and genomic elasticity [1, 2]. Our most successful therapies to date inhibit 
proliferation via the estrogen receptor (ER) and HER2 pathways or induce apoptosis via 
cytotoxic chemotherapy or ionizing radiation. Targeted therapeutic advances for patients 
with tumors that lack ER and HER2 will require identification of novel ‘driver’ mutations or 
new strategies that attack other hallmarks of malignancy.
As most patients succumb to metastatic disease, there is well-justified interest in targeting 
the metastatic cascade. Nm23, the prototype metastasis suppressor gene (MSG) first 
described in 1988 [3], was identified on the basis of its reduced expression in highly 
metastatic tumors or cell lines, as compared to tumorigenic but poorly metastatic specimens. 
Unlike classical tumor suppressor genes, MSGs suppress in vivo metastatic capacity without 
impacting the growth of the primary tumor [4, 5]. Rather than simply inhibiting invasion, 
which has often been completed by the time a patient walks into the clinic, MSGs inhibit 
colonization and outgrowth of tumors at distant metastatic sites [6, 7]. This later window of 
progression provides a substantial therapeutic opportunity.
But how does one restore the function (in this case the suppressive effect) of a gene 
or protein that has been lost? Reduced Nm23 protein expression, not allelic deletion or 
mutations, was correlated with poor patient survival [8], prompting a search for methods 
to restore expression. Molecular analyses of the Nm23 promoter identified transcription 
factor binding sites regulated by glucocorticoid response elements, suggesting that Nm23 
expression might be partly regulated by the glucocorticoid receptor (GR) [4, 9]. Indeed 
in preclinical studies, the atypical glucocorticoid medroxyprogesterone acetate (MPA) 
increased Nm23 expression in vitro and inhibited metastasis in vivo in aggressive HR­
negative breast cancer models in a GR-dependent manner [10].
MPA has a long clinical history but was largely abandoned in favor of tamoxifen over three 
decades ago [11]. Although initially developed as an alternative hormonal therapy, several 
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studies documented responses in patients with ER-negative tumors [12-15]. No optimal 
dose or schedule was identified with several studies finding similar response rates with 
doses ranging from 400 to 1,400 mg per day [16-18]. Studies incorporating pharmacokinetic 
analysis found higher MPA trough concentrations in responding versus non-responding 
patients. The lack of clear dose–response relationship may be partially explained by the 
significant inter-patient variation in bioavailability and metabolism. A retrospective analysis 
of 380 patients treated with varying doses of MPA confirmed a relationship between 
systemic exposure and efficacy [19].
Additionally, MPA increased expression of anti-angiogenic peptides thrombospondin 
(TSP-1) and plasminogen activator inhibitor type I (PAI-1) (unpublished data); culture 
supernatant from MPA treated HR-negative breast cancer cells did not support angiogenesis 
in an ex vivo aortic ring assay [20, 21]. Interestingly, prolonged in vitro exposure of 
endothelial cells to low concentrations of several different chemotherapeutic agents also 
markedly induces gene and protein expression of TSP-1. Although the contribution of 
the antiangiogenic versus direct antitumor effect of low-dose chemotherapy has been 
debated, low-dose cyclophosphamide (but not high-dose intermittent cyclophosphamide) 
was ineffective in xenograft models implanted in TSP-1-null mice [22], suggesting that 
induction is TSP-1 is required for efficacy. As both MPA and low-dose cyclophosphamide 
induce TSP-1, this phase II study was designed to explore the clinical efficacy and 
biologic activity of MPA, alone and in combination with low-dose cyclophosphamide and 
methotrexate (ldCM), in patients with metastatic HR-negative breast cancer.
Patients and methods
Trial eligibility
Postmenopausal women with HR-negative (both estrogen and progesterone) metastatic 
breast cancer were eligible if they had received no more than three prior chemotherapy 
regimens for metastatic disease. In addition, patients were required to have a performance 
status ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale with adequate renal 
(creatinine ≤2.5 mg/dL), hepatic (total bilirubin ≤2.0 mg/dL; AST and ALT <2.0 times 
upper limit of normal or ≤5 × normal in patients with liver involvement), and hematologic 
(ANC ≥1,000/mm3; platelets ≥75,000/mm3) function. Patients were excluded if they had 
experienced a deep venous thrombosis or pulmonary embolism within 12 months of study 
entry or if they had extensive pleural effusion or ascites. Patients with asymptomatic, 
treated central nervous system metastasis were eligible provided chronic steroid therapy 
was not required. Each participating Institutional Review Board approved the protocol, and 
all patients provided individual written informed consent prior to screening and study entry.
Treatment plan
MPA was obtained from Spectrum Chemicals (New Brunswick, NJ) and compounded 
into 250 mg capsules (Chao Center for Industrial Pharmacy and Contract Manufacturing, 
West Lafayette, Indiana). Patients in cohort one received MPA 1,000 mg continuously as a 
single daily oral dose; 28 days was considered one cycle. As previous studies had reported 
significant variability in bioavailability and metabolism, we assessed drug exposure after 
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10–14 days of therapy. If the trough MPA serum concentration obtained on day 10–14 was 
<50 ng/ml (the target concentration based on preclinical data and prior clinical trials), the 
MPA dose was increased to 1,500 mg/day. Additional trough PK samples were obtained 
to monitor drug exposure, but no further dose adjustments were made based on those 
subsequent MPA levels.
As both MPA and low-dose cyclophosphamide increase TSP-1 expression in vivo, we 
hypothesized synergistic activity with low-dose cyclophosphamide in combination with 
MPA. Therefore, patients in cohort two also received low-dose oral cyclophosphamide 50 
mg/day continuously with methotrexate 2.5 mg twice daily on Days 1 and 2 (ldCM) of each 
week; 28 days was considered one cycle. MPA treatment and dose escalation were identical 
to cohort one.
Safety and efficacy assessments
Patients were evaluated clinically every 4 weeks. Laboratory assessments including 
complete blood count and serum chemistry were assessed at each evaluation. Toxicity was 
assessed based on the National Cancer Institute Common Toxicity Criteria (NCI-CTC v3.0). 
MPA could be held or reduced for Grade 3 or greater thromboembolism, weight gain, 
or peripheral edema. ldCM could be held or reduced for Grade 3 or greater neutropenia, 
mucositis, or hepatic dysfunction. Disease status was assessed according to the Response 
Evaluation Criteria for Solid Tumors (RECIST) [23] criteria every 8 weeks or more 
frequently when clinically indicated.
Drug exposure and pharmacodynamics
Serum for determination of MPA trough concentration was obtained prior to MPA 
administration once between Days 10–14 and after 4 and 8 weeks of therapy. Samples 
were obtained in a standard 10 ml red top tube and allowed to clot at room temperature for 
30 min. Serum was separated by centrifugation at 3,000 × g for 30 min and stored at −20 
°C in 1 ml aliquots for later analysis; triplicate aliquots were preserved for each patient at 
each time point. MPA was quantified using norgestimate (NGM) as the internal standard, 
liquid–liquid extraction, and HPLC–MS/MS (ABSciex4000, Applied Biosystems). MPA and 
NGM were separated by gradient mobile phase (acetonitrile:formic acid) and HPLC using a 
biphenyl column (Restek 5 μm 50 × 4.6 mm). The Q1/Q3s for MPA and NGM were 387/327 
and 370/124, respectively. The lower limit of quantification (LOQ) is 1 ng/mL using 100 μL 
of serum.
Plasma samples to measure TSP-1, PAI-1 antigen, and PAI-1 activity were obtained at 
baseline, after 2, 4, and 8 weeks of therapy. Samples were obtained in a heparinized green 
top tube, separated by centrifugation at 3,000 g for 30 min within 2 hours, and stored at 
−20 °C in 1 ml aliquots for later analysis; triplicate aliquots were preserved for each patient 
at each time point. All samples were measured in duplicate using commercially available 
enzyme linked immunosorbant assays (ELISA, Chemicon, Temecula, CA and DiaPharma, 
West Chester, OH). All samples with a coefficient of variation >10 % were repeated. The 
assays have the following limits of detection: TSP-1 9.77 ng/ml, PAI-1 antigen 0.5 ng/ml, 
and PAI-1 activity 0.5 ng/ml.
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Archived primary tumor and serial skin biopsy samples (baseline and C2D1) were stained 
for Nm23 using an affinity purified polyclonal rabbit anti-Nm23-H1/H2 antibody (Cymbus, 
Southampton, United Kingdom). An isotype-matched control antibody (goat anti-rabbit 
immunoglobulin G; Santa Cruz Biotechnology, Santa Cruz, CA) was used on a second 
independent section to control for nonspecific binding. In brief, sections are deparaffinized 
in xylene, dehydrated in 100 % ethanol, rehydrated in 95 % ethanol and phosphate-buffered 
saline (PBS), and blocked sequentially with hydrogen peroxide and goat serum. Antigen 
retrieval was accomplished by incubating the slides in 10 m M citrate buffer, pH 3.0, for 
30 min at 37 °C. Slides were incubated with primary antibody (diluted 1:5 in PBS with 
1 % goat serum) in a humidified chamber overnight at room temperature. Staining was 
visualized using the Vectastain ABC kit and the DAB Substrate kit (Vector Laboratories, 
Burlingame, CA). Staining intensities were graded (0–3+) by a single pathologist (MM) 
blinded to treatment group, response, and timing of skin biopsy.
Statistical analyses
Cohorts one and two were analyzed independently for toxicity and efficacy; there were no 
plans for formal comparison between the treatment groups. A regimen that produced at least 
a 20 % clinical benefit rate (CR + PR + SD ≥ 6 months) would be considered worthy of 
further study in this patient population. A serial optimal two-stage design for each regimen 
with 3 % type I error probability for H0:p = .1 and 80 % power for H1:p = .3 required 
between 15 and 25 patients per treatment cohort. 15 patients were treated in the first stage 
of each cohort. If fewer than 2 patients among the 15 derived clinical benefit, then regimen 
would be rejected. If 2 or more patients derived clinical benefit, then an additional 10 
patients would be enrolled. If 5 or fewer patients among the total 25 derived clinical benefit, 
then regimen would be rejected. Patients were enrolled sequentially beginning with cohort 
one. Enrollment to cohort 2 began upon completion of cohort one.
Secondary endpoints included characterization of MPA exposure based on trough levels, 
impact of MPA on circulating angiogenic peptides and Nm23 expression in skin. The change 
in angiogenic peptides from baseline to C1D15 and C2D1 was assessed using the repeated 
measures ANOVA and Bonferroni’s multiple comparison test when appropriate; Nm23 skin 
expression between baseline and C2D1 was compared using the Wilcoxin signed rank test. 
Additionally, progression free survival (PFS) was analyzed using the Kaplan–Meier method.
Results
Patient population
Thirty patients were enrolled, 14 in cohort 1 and 16 in cohort 2. Patient characteristics are 
shown in Table 1. Patients were heavily pre-treated with the majority having visceral disease 
at study entry. All patients were evaluable for toxicity. Seven patients (2 in cohort 1 and 5 
in cohort 2) had symptomatic decline and clinical evidence of rapid progression that was not 
confirmed radiographically.
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Toxicity and treatment delivered
MPA was generally well tolerated with few patients experiencing Grade 3 or 4 toxicities 
(Table 2). Two patients in cohort 1 required dose reductions due to grade 2 nausea and 
rash. ldCM did not induce significant myelosuppression even in this heavily pretreated 
population. Three patients in cohort 2 required dose reduction of ldCM and MPA due to 
toxicity. Treatment was held due to nausea, emesis, and dehydration in one patient who later 
developed grade 4 renal failure. Evaluation found rapidly progressive disease, but a possible 
relationship to study therapy could not be excluded. One patient had increased transaminases 
that improved with dose reduction. Doses were reduced due to grade 2 mucositis and fatigue 
in one patient. There were no thromboembolic events, fluid retention, pleural effusions, or 
weight gain to suggest significant estrogenic exposure.
Efficacy
There were no objective responses. Five patients (3 in cohort 1 and 2 in cohort 2) had 
stable disease, but only 2 patients remained stable for ≥6 months. One patient with prior 
anthracycline and capecitabine therapy had a stable lung lesion for 7 months on MPA 
monotherapy. One patient with prior anthracycline, taxane, capecitabine, gemcitabine, and 
vinorelbine exposure had stable lymph node metastases with ldCM + MPA for 8 months. 
Overall median PFS was approximately 1.8 months in both cohorts.
Drug exposure and pharmacodynamics
Trough MPA concentrations are shown in Table 3. Although the sample size is too 
small for definitive conclusions, there was no obvious difference in MPA exposure with 
concomitant ldCM. Nearly all patients required dose escalation. Overall exposure was less 
than anticipated with just over half of patients ever achieving concentrations >50 ng/mL. 
Both patients with prolonged stable disease had MPA concentrations >50 ng/mL after initial 
dose escalation. Prior studies had suggested a decrease in MPA exposure at the time of 
disease progression [24], but MPA remained >50 ng/mL at progression in both patients who 
derived clinical benefit.
Serial plasma samples for measurement of TSP-1, PAI-1 antigen, and PAI-1 activity were 
available for 12 patients in cohort 1 and 13 patients in cohort 2 (Fig. 1). PAI-1 antigen 
increased after MPA monotherapy (p < 0.001), but the difference was not significant 
when corrected for multiple testing. No other changes in plasma angiogenic peptides were 
identified. Archived primary tumor samples were obtained in 19 patients; Nm23 was absent 
or expressed at low levels (0 or 1 +) in 63 % of tumors. Serial skin biopsies were evaluable 
for 7 patients in cohort 1 and 6 patients in cohort 2 (Fig. 2). Nm23 expression in skin was 
unchanged during MPA monotherapy but increased significantly after 4 weeks of treatment 
with MPA + ldCM (p = 0.03).
Discussion
Despite a sound preclinical foundation, MPA monotherapy had little clinical or biologic 
activity in patients with advanced HR-negative metastatic breast cancer in this prospective, 
phase II trial. The activity of ldCM in our study was also less than that previously reported. 
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Colleoni had reported an objective response rate of 19 % with 31 % of patients achieving 
clinical benefit [25]. However, the patients in Colleoni’s trial were less heavily pretreated, 
and the majority of responding patients (4 of 12) had hormone sensitive disease. Colleoni 
had also reported a reduction in serum vascular endothelial growth factor (VEGF) after 2 
months of ldCM therapy, though the change in serum VEGF did not correlate with response 
or clinical benefit. As release of VEGF stored in platelets complicates analysis of circulating 
VEGF levels [26-28] and changes in TSP-1 were more closely associated with activity of 
MPA and ldCM in preclinical models, we did not measure VEGF in our patients.
Several important limitations may have contributed to the limited efficacy we observed. 
First, the complexity of HR-negative breast cancer has increasingly been recognized [29-31]. 
Although most HR-negative breast cancer cell lines [32] and at least 25 % of HR-negative 
primary breast cancers express glucocorticoid receptor (GR) [33], levels vary significantly. 
We did not require GR expression for study entry, and the limited number of archived 
samples available precluded any assessment of benefit based on GR expression. Second, 
despite real-time assessment of MPA trough concentration and mid-cycle dose escalation, 
few patients reached concentrations in the potentially therapeutic range. Interestingly, both 
patients with clinical benefit had concentrations above the potential therapeutic threshold 
50 ng/ml based on previous preclinical and clinical studies. Third, we did not assess 
changes in tumor Nm-23 levels. We were concerned that requiring serial tumor biopsy 
would be unacceptable to some patients and would place patients with disease limited to 
less accessible sites (i.e., lung) at greater risk. In preclinical studies, MPA altered Nm23 
expression in skin biopsies, providing rationale for including skin biopsies as a correlate 
in this trial. We intended the skin biopsies as only a correlate of biologic activity and 
potentially effective drug exposure rather than as a direct correlate of clinical activity. Given 
the limited drug exposure, the lack of modulation of Nm23, TSP, and PAI-1 is not surprising. 
The apparent increase in Nm23 expression after combined MPA + ldCm must be interpreted 
with caution given the small sample size and multiple correlatives assessed. In addition, 
while changes in skin expression correlated with changes in tumor Nm23 expression in 
preclinical models (unpublished data), the correlation in patients remains unknown.
Finally, metastasis is a complicated multistep process, and reintroduction of one MSG may 
not be sufficient to alter tumor growth. Since the initial identification of Nm-23 as the 
prototype metastasis suppressor gene, it has become clear that Nm-23 (and other MSGs) has 
more functions than were originally anticipated [34]. Although reduced Nm23 expression 
has been generally correlated with increased metastatic potential, this correlation does not 
hold true for all cancer types. Neuroblastoma provides a notable exception, where increased 
Nm23 expression is correlated with more aggressive disease. In neuroblastoma, a mutant 
nm23 has been identified [35, 36], unlike in solid tumors such as breast cancer, where 
decreased Nm23 expression has not been linked to mutations in the Nm23-H1 gene [37].
Importantly, preliminary study was never intended to be definitive but rather to provide an 
initial exploration of the biological and clinical activity, deciding a priori that a clinical 
benefit rate of 20 % or greater with either regimen (MPA monotherapy or MPA + ldoCM) 
would be worthy of further study. In retrospect, the level of activity was an ambitious 
goal in this pretreated population. Although negative in the sense that the primary endpoint 
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was not reached, this trial highlights the difficulty in studying anti-metastatic agents. The 
development of the anti-metastatic therapies, like that of other anti-proliferative rather than 
cytotoxic compounds, poses a challenge in clinical trial design. The reinduction of MSGs 
implies reduction or delay in the development of new metastatic lesions rather than time 
to progression or objective tumor response as the proper primary endpoint. Unfortunately, 
delay in the development of new lesions cannot be determined with certainty in uncontrolled 
trials, and the benefit of preventing outgrowth of new lesions while existing lesions continue 
to progress is uncertain. Intuitively, the impact of reinduction of metastases suppressor 
gene (MSG) expression is expected to be greatest in patients with micrometastatic disease
—an intuition that will require commitment of substantial human and financial resources 
to a randomized trial, in the adjuvant or post-neoadjuvant therapy settings, to test [38]. 
Alternatively, trials in patients who have received limited treatment for metastatic disease 
could be conducted with the primary endpoint being development of a new, rather than 
further growth of a preexisting metastasis, as the primary endpoint [39]. The negative results 
we report here should not dampen enthusiasm for the study of other anti-metastatic agents in 
patients with less advanced disease.
Acknowledgments
Supported by NIH/NCI P30 CA082709-AV-133 (Avon Partners for Progress Supplement) and the Breast Cancer 
Research Foundation (KDM). In addition, we are grateful for the funding support to the Translational Breast Cancer 
Research Consortium (TBCRC) from The AVON Foundation, The Breast Cancer Research Foundation, and Susan 
G. Komen for the Cure.
References
1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70 [PubMed: 10647931] 
2. Sledge GW Jr, Miller KD (2003) Exploiting the hallmarks of cancer: the future conquest of breast 
cancer. Eur J Cancer 39(12):1668–1675 [PubMed: 12888360] 
3. Steeg PS, Bevilacqua G, Pozzatti R, Liotta LA, Sobel ME (1988) Altered expression of NM23, 
a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of 
experimental metastasis. Cancer Res 48(22):6550–6554 [PubMed: 2460224] 
4. Ouatas T, Halverson D, Steeg P (2003) Dexamethasone and medroxyprogesterone acetate elevate 
Nm23-H1 metastasis suppressor expression in metastatic human breast carcinoma cells: New uses 
for old compounds. Clin Cancer Res 9:3763–3772 [PubMed: 14506169] 
5. Yoshida B, Sokoloff M, Welch D, Rinker-Schaeffer C (2000) Metastasis-suppressor genes: a review 
and perspective on an emerging field. J Natl Cancer Inst 92:1717–1730 [PubMed: 11058615] 
6. Leone A, Flatow U, King C, Sandeen M, Margulies I, Liotta L, Steeg P (1991) Reduced tumor 
incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. 
Cell 65:25–35 [PubMed: 2013093] 
7. Leone A, Flatow U, VanHoutte K, Steeg P (1993) Transfection of human nm23-H1 into the human 
MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization, and 
enzymatic activity. Oncogene 8:2325–2333 [PubMed: 8395676] 
8. Cropp C, Lidereau R, Leone A, Liscia D, Cappa A, Campbell G, Barker E, Doussal V, Steeg P, 
Callahan Ret al. (1994) NME1 protein expression and loss of heterozygosity mutations in primary 
human breast tumors. J Natl Cancer Inst 86:1167–1169 [PubMed: 8028038] 
9. Ouatas T, Clare S, Hartsough M, DeLaRosa A, Steeg P (2002) MMTV-associated transcription 
factor binding sites increase nm23-H1 metastasis suppressor gene expression in human breast 
carcinoma cell lines. Clin Exp Metast 19:35–42
10. Palmieri D, Halverson D, Ouatas T, Salerno M, Johnson J, Figg W, Hollingshead M, Hursting 
S, Berigan D, Steinberg Set al. (2005) Medroxyprogesterone acetate elevation of Nm23-H1 
Miller et al. Page 8













metastasis suppressor expression in hormone receptor—negative breast cancer. J Natl Cancer Inst 
97:632–642 [PubMed: 15870434] 
11. Van Veelen H, Willemse P, Tjabbes Tet al. (1986) Oral high-dose medroxyprogesterone acetate 
versus tamoxifen. Cancer 58:7–13 [PubMed: 2939943] 
12. Nishimura R, Nagao K, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M, Higuchi A, 
Ikeda K (1997) Predictive value of serum medroxyprogesterone acetate concentration for response 
or recurrent breast cancer. Eur J Cancer 33(9):1407–1412 [PubMed: 9337682] 
13. Tashiro H, Nomura Y (1995) Mitomycin C, methotrexate, and vincristine with 
medroxyprogesterone acetate or prednisolone for doxorubicin resistant advanced breast cancer–a 
randomized control study. Anticancer Res 15(5B):2229–2237 [PubMed: 8572630] 
14. Koyama H, Tominaga T, Asaishi K, Abe R, Iino Y, Enomoto K, Miura S, Nomura Y, Nakazato 
H, Abe O (1999) A randomized controlled comparative study of oral medroxyprogesterone acetate 
1,200 and 600 mg in patients with advanced or recurrent breast cancer. Oncology 56(4):283–290 
[PubMed: 10343191] 
15. Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, Dewar J, Lunn M, Flower 
C, Gill PGet al. (1997) Medroxyprogesterone acetate addition or substitution for tamoxifen in 
advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand 
Breast Cancer Trials Group. J Clin Oncol 15(9):3141–3148 [PubMed: 9294477] 
16. Hortobagyi GN, Buzdar AU, Frye D, Yap HY, Hug V, Pinnamaneni K, Fraschini G, Halvorson HC, 
Blumenschein GR (1985) Oral medroxyprogesterone acetate in the treatment of metastatic breast 
cancer. Breast Cancer Res Treat 5(3):321–326 [PubMed: 3161565] 
17. Gallagher CJ, Cairnduff F, Smith IE (1987) High dose versus low dose medroxyprogesterone 
acetate: a randomized trial in advanced breast cancer. Eur J Cancer Clin Oncol 23(12):1895–1900 
[PubMed: 2963746] 
18. Davila E, Vogel CL, East D, Cairns V, Hilsenbeck S (1988) Clinical trial of high-dose oral 
medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the 
literature. Cancer 61(11):2161–2167 [PubMed: 2966667] 
19. Pannuti F, Camaggi CM, Strocchi E, Martoni A (1986) MPA at high doses in advanced breast 
cancer: a statistical evaluation. Chemioterapia 5(3):159–163 [PubMed: 2941172] 
20. Zhou L, Isenberg J, Cao Z, Roberts D (2006) Type I collagen is a molecular target for inhibition of 
angiogenesis by endogenous thrombospondin-1. Oncogene 25:536–545 [PubMed: 16247480] 
21. Isenberg J, Calzada M, Zhou L, Guo N, Lawler J, Wang XQ, Frazier W, Roberts D (2005) 
Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular 
smooth muscle cell responses to platelet-derived growth factor. Matrix Biol 24:110–123 [PubMed: 
15890262] 
22. Bocci G, Francia G, Man S, Lawler J, Kerbel RS (2003) Thrombospondin 1, a mediator of 
the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 
100(22):12917–12922 [PubMed: 14561896] 
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van 
Glabbeke M, van Oosterom AT, Christian MCet al. (2000) New guidelines to evaluate the response 
to treatment in solid tumors. European Organization for Research and Treatment of Cancer, 
National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer 
Inst 92(3):205–216 [PubMed: 10655437] 
24. Nishimura R, Nagao K, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M, Higuchi A, 
Ikeda K (1997) Predictive value of serum medroxyprogesterone acetate concentration for response 
in advanced or recurrent breast cancer. Eur J Cancer 33(9):1407–1412 [PubMed: 9337682] 
25. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando 
L, Cinieri Set al. (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast 
cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann 
Oncol 13(1):73–80
26. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, 
Bicknell R, Walker JJet al. (2000) Vascular endothelial growth factor (VEGF) in breast cancer: 
comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. 
Cancer Res 60(11):2898–2905 [PubMed: 10850435] 
Miller et al. Page 9













27. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo 
HM (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3(12 Pt 
1):2187–2190 [PubMed: 9815613] 
28. Wynendaele W, Derua R, Hoylaerts MF, Pawinski A, Waelkens E, de Bruijn EA, Paridaens R, 
Merlevede W, van Oosterom AT (1999) Vascular endothelial growth factor measured in platelet 
poor plasma allows optimal separation between cancer patients and volunteers: a key to study an 
angiogenic marker in vivo? Ann Oncol 10(8):965–971 [PubMed: 10509160] 
29. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, 
Williams CF, Zhu SX, Lee JCet al. (1999) Distinctive gene expression patterns in human 
mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 96(16):9212–9217 
[PubMed: 10430922] 
30. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) 
Identification of human triple-negative breast cancer subtypes and preclinical models for selection 
of targeted therapies. J Clin Invest 121(7):2750–2767 [PubMed: 21633166] 
31. Perou C, Sorlie T, Eisen Met al. (2000) Molecular portraits of human breast tumours. Nature 
406:747 [PubMed: 10963602] 
32. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD (2001) Glucocorticoid receptor­
mediated protection from apoptosis is associated with induction of the serine/threonine survival 
kinase gene, sgk-1. J Biol Chem 276(20):16649–16654 [PubMed: 11278764] 
33. Pan D, Kocherginsky M, Conzen SD (2011) Activation of the glucocorticoid receptor is associated 
with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res 71(20):6360–6370 
[PubMed: 21868756] 
34. Steeg PS, Zollo M, Wieland T (2011) A critical evaluation of biochemical activities reported 
for the nucleoside diphosphate kinase/Nm23/Awd family proteins: opportunities and missteps in 
understanding their biological functions. Naunyn-Schmiedeberg’s Arch Pharmacol 384(4–5):331–
339 [PubMed: 21611737] 
35. Chang CL, Zhu XX, Thoraval DH, Ungar D, Rawwas J, Hora N, Strahler JR, Hanash SM, Radany 
E (1994) Nm23-H1 mutation in neuroblastoma. Nature 370(6488):335–336 [PubMed: 8047138] 
36. Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, Stram D, Slamon DJ, 
Steeg PS (1993) Evidence for nm23 RNA overexpression, DNA amplification and mutation in 
aggressive childhood neuroblastomas. Oncogene 8(4):855–865 [PubMed: 8384356] 
37. Leone A, Flatow U, VanHoutte K, Steeg PS (1993) Transfection of human nm23-H1 into 
the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, 
colonization and enzymatic activity. Oncogene 8(9):2325–2333 [PubMed: 8395676] 
38. Steeg PS (2012) Perspective: the right trials. Nature 485(7400):S58–59 [PubMed: 22648501] 
39. Brabletz T, Lyden D, Steeg PS, Werb Z (2013) Roadblocks to translational advances on metastasis 
research. Nat Med 19(9):1104–1109 [PubMed: 24013756] 
Miller et al. Page 10














Plasma concentration of TSP-1 (a), PAI-1 antigen (b), and PAI-1 activity (c) was assessed 
in 12 patients in cohort 1 and 13 patients in cohort 2. PAI-1 antigen increased after MPA 
monotherapy (p < 0.001), but the difference was not significant when corrected for multiple 
testing. (C1D15 = Cycle 1, Day 15, C2D1 = Cycle 2, Day 1)
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Punch skin biopsies were assessed for Nm-23 expression at baseline and after 4 weeks 
of therapy. Nm23 expression in skin was unchanged during MPA monotherapy (a) but 
increased significantly after 4 weeks of treatment with MPA + ldCM (B, p = 0.03). (C2D1 = 
Cycle 2, Day 1)
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Median age 59 (35–79) 53 (39–80) 55 (35–80)
Race
  Caucasian 9 (64 %) 12 (75 %) 21 (70 %)
  African American 5 (36 %) 3 (19 %) 8 (26 %)
  Asian 0 1 (6 %) 1 (3 %)
ECOG PS*
  0 4 (29 %) 8 (50 %) 12 (40 %)
  1 8 (57 %) 6 (38 %) 14 (46 %)
  2 1 (7 %) 1 (6 %) 2 (7 %)
  Visceral disease 8 (57 %) 15 (94 %) 23 (77 %)
Prior therapy
  Anthracycline 14 (100 %) 13 (81 %) 27 (90 %)
  Taxane 13 (93 %) 13 (81 %) 26 (87 %)
  Platinum 7 (50 %) 10 (62 %) 17 (57 %)
  Bevacizumab 10 (71 %) 7 (44 %) 17 (57 %)
  Capecitabine 5 (36 %) 10 (62 %) 15 (50 %)
  Gemcitabine 4 (29 %) 6 (37 %) 10 (33 %)
  Vinorelbine 6 (43 %) 3 (19 %) 9 (30 %)
*
Eastern Cooperative Oncology Group performance status missing in 2 patients























2 3 4 2 3 4 2 3 4
Nausea 1 0 0 0 0 0 1 0 0
Dysgeusia 0 0 0 1 0 0 1 0 0
Mucositis 0 0 0 1 1 0 1 1 0
Dysphagia 0 0 0 0 1 0 0 1 0
Fatigue 0 0 0 2 1 0 2 1 0
Pain 3 0 0 1 0 0 4 0 0
Dyspnea 0 1 0 0 1 0 0 2 0
Hot flashes 0 0 0 1 0 0 1 0 0
Irregular menses 0 0 0 1 0 0 1 0 0
Insomnia 0 0 0 1 0 0 1 0 0
Diaphoresis 1 0 0 0 0 0 1 0 0
Rash 1 0 0 1 0 0 2 0 0
Hypokalemia 0 1 0 0 0 0 0 1 0
Transaminase elevated 0 0 0 1 0 0 1 0 0
Alkaline phosphatase elevated 0 0 0 1 0 0 1 0 0
Renal failure 0 0 0 0 0 1 0 0 1
Dehydration 0 0 0 0 1 0 0 1 0
Worst toxicity reported per patient based on NCI-CTC v3.0
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